(Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in ...
Merck (MRK) said its experimental eye drug remigromig improved vision in patients with a diabetes-related eye disease, meeting the main goal of a late-stage clinical trial. However, patients receiving ...
Merck presents one-year results from the pivotal phase 2b/3 BRUNELLO study of remigromig in adults with diabetic macular edema at AAO 2026: Rahway, New Jersey Tuesday, October 13, ...
Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at ...
MSD's return to the ophthalmology field after decades of absence, via the acquisition of EyeBio in a $3 billion deal in 2024, has been charged up with a positive phase 3 trial in diabetic macular ...
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema ...
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results